


DOCKET NO.: 257650US0PCT



15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1614

Kazuya HAYASHI, et al.

SERIAL NO: 10/506,422

ATTENTION:

FILING RECEIPT CORRECTIONS

FILED: September 2, 2004

FOR: NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Office of Initial Patent Examination
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Patent Office is requested to provide a corrected Official Filing Receipt for the following. PLEASE NOTE THAT THE FOREIGN PRIORITY INFORMATION HAS BEEN OMITTED. IT SHOULD READ AS FOLLOWS: **JAPAN 2002-60618 03/06/2002**

No fees are required. If you have any questions, please do not hesitate to contact us.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Corwin P. Umbach, Ph.D.
Registration No. 40,211


Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/05)



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/506,422	09/02/2004	1614	920	254850US0PCT 76		10	1

22850
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

CONFIRMATION NO. 1258

CORRECTED FILING RECEIPT



OC000000015370675

Date Mailed: 03/07/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Kazyua Hayashi, Uozu-shi, JAPAN;
Katsuji Ojima, Toyama-shi, JAPAN;
Kozo Hori, Kosugi-machi, JAPAN;
Noriyuki Okujo, Kishiwada-shi, JAPAN;
Junichi Mitsuyama, Kamiichi-machi, JAPAN;
Kazuto Kunitani, Kosugi-machi, JAPAN;
Keisuke Tohdo, Toyama-shi, JAPAN;

Assignment For Published Patent Application

Toyama Chemical Co., Ltd, Tokyo, JAPAN

Power of Attorney: The patent practitioners associated with Customer Number 22850.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/02506 03/04/2003

Foreign Applications

JAPAN 2002-60618 03/08/2002

If Required, Foreign Filing License Granted: 03/07/2005

RECEIVED: **3/10/05**
OBLON, SPIVAK, MCCLELLAND
MAIER & NEUSTADT, P.C.

DOCKETING DEPT

Initials/Date Docketed: **UG 3/10/05**
Type of Resp(s): _____
Due Date(s): _____

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/506,422**

Projected Publication Date: 05/05/2005

Non-Publication Request: No

Early Publication Request: No

Title

Novel arylamidine derivative or salt thereof

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).